UNLABELLED: Strontium ranelate appears to influence more than alendronate distal tibia bone microstructure as assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biomechanically relevant parameters as assessed by micro-finite element analysis (μFEA), over 2 years, in postmenopausal osteoporotic women. INTRODUCTION:Bone microstructure changes are a target in osteoporosis treatment to increase bone strength and reduce fracture risk. METHODS: Using HR-pQCT, we investigated the effects on distal tibia and radius microstructure of strontium ranelate (SrRan; 2 g/day) or alendronate (70 mg/week) for 2 years in postmenopausal osteoporotic women. This exploratory randomized, double-blind trial evaluated HR-pQCT and FEA parameters, areal bone mineral density (BMD), and bone turnover markers. RESULTS: In the intention-to-treat population (n = 83, age: 64 ± 8 years; lumbar T-score: -2.8 ± 0.8 [DXA]), distal tibia Cortical Thickness (CTh) and Density (DCort), and cancellous BV/TV increased by 6.3%, 1.4%, and 2.5%, respectively (all P < 0.005), with SrRan, but not with alendronate (0.9%, 0.4%, and 0.8%, NS) (P < 0.05 for all above between-group differences). Difference for CTh evaluated with a distance transformation method was close to significance (P = 0.06). The estimated failure load increased with SrRan (+2.1%, P < 0.005), not with alendronate (-0.6%, NS) (between-group difference, P < 0.01). Cortical stress was lower with SrRan (P < 0.05); both treatments decreased trabecular stress. At distal radius, there was no between-group difference other than DCort (P < 0.05). Bone turnover markers decreased with alendronate; bALP increased (+21%) and serum-CTX-I decreased (-1%) after 2 years of SrRan (between-group difference at each time point for both markers, P < 0.0001). Both treatments were well tolerated. CONCLUSIONS: Within the constraints of HR-pQCT method, and while a possible artefactual contribution of strontium cannot be quantified, SrRan appeared to influence distal tibia bone microstructure and FEA-determined biomechanical parameters more than alendronate. However, the magnitude of the differences is unclear and requires confirmation with another method.
RCT Entities:
UNLABELLED: Strontium ranelate appears to influence more than alendronate distal tibia bone microstructure as assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biomechanically relevant parameters as assessed by micro-finite element analysis (μFEA), over 2 years, in postmenopausal osteoporoticwomen. INTRODUCTION: Bone microstructure changes are a target in osteoporosis treatment to increase bone strength and reduce fracture risk. METHODS: Using HR-pQCT, we investigated the effects on distal tibia and radius microstructure of strontium ranelate (SrRan; 2 g/day) or alendronate (70 mg/week) for 2 years in postmenopausal osteoporoticwomen. This exploratory randomized, double-blind trial evaluated HR-pQCT and FEA parameters, areal bone mineral density (BMD), and bone turnover markers. RESULTS: In the intention-to-treat population (n = 83, age: 64 ± 8 years; lumbar T-score: -2.8 ± 0.8 [DXA]), distal tibia Cortical Thickness (CTh) and Density (DCort), and cancellous BV/TV increased by 6.3%, 1.4%, and 2.5%, respectively (all P < 0.005), with SrRan, but not with alendronate (0.9%, 0.4%, and 0.8%, NS) (P < 0.05 for all above between-group differences). Difference for CTh evaluated with a distance transformation method was close to significance (P = 0.06). The estimated failure load increased with SrRan (+2.1%, P < 0.005), not with alendronate (-0.6%, NS) (between-group difference, P < 0.01). Cortical stress was lower with SrRan (P < 0.05); both treatments decreased trabecular stress. At distal radius, there was no between-group difference other than DCort (P < 0.05). Bone turnover markers decreased with alendronate; bALP increased (+21%) and serum-CTX-I decreased (-1%) after 2 years of SrRan (between-group difference at each time point for both markers, P < 0.0001). Both treatments were well tolerated. CONCLUSIONS: Within the constraints of HR-pQCT method, and while a possible artefactual contribution of strontium cannot be quantified, SrRan appeared to influence distal tibia bone microstructure and FEA-determined biomechanical parameters more than alendronate. However, the magnitude of the differences is unclear and requires confirmation with another method.
Authors: Ego Seeman; Pierre D Delmas; David A Hanley; Deborah Sellmeyer; Angela M Cheung; Elizabeth Shane; Ann Kearns; Thierry Thomas; Steven K Boyd; Stephanie Boutroy; Cesar Bogado; Sharmila Majumdar; Michelle Fan; Cesar Libanati; Jose Zanchetta Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Monique E Arlot; Yebin Jiang; Harry K Genant; Jenny Zhao; Brigitte Burt-Pichat; Jean-Paul Roux; Pierre D Delmas; Pierre J Meunier Journal: J Bone Miner Res Date: 2008-02 Impact factor: 6.741
Authors: Andrew J Burghardt; Galateia J Kazakia; Sweta Ramachandran; Thomas M Link; Sharmila Majumdar Journal: J Bone Miner Res Date: 2010-05 Impact factor: 6.741
Authors: Kyle K Nishiyama; Adi Cohen; Polly Young; Ji Wang; Joan M Lappe; X Edward Guo; David W Dempster; Robert R Recker; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Fabio M Ulivieri; Barbara C Silva; Francesco Sardanelli; Didier Hans; John P Bilezikian; Renata Caudarella Journal: Endocrine Date: 2014-05-23 Impact factor: 3.633
Authors: Piet Geusens; Roland Chapurlat; Georg Schett; Ali Ghasem-Zadeh; Ego Seeman; Joost de Jong; Joop van den Bergh Journal: Nat Rev Rheumatol Date: 2014-03-04 Impact factor: 20.543
Authors: Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Robert M Neer; Yuli Zhu; Nicholas Derrico; Hang Lee; Mary L Bouxsein; Benjamin Z Leder Journal: J Bone Miner Res Date: 2015-01 Impact factor: 6.741